Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML
Nature Communications, 2020 The oncogene MLL is frequently translocated in leukemia, resulting in oncogenic fusion proteins. Here, the authors report a temporally controlled mouse model of MLL-ENL driven leukemia AND identify therapeutic targets associated with early MLL-ENL driven
Silvia Basilico +13 more
doaj +1 more source
Cell death pathways as therapeutic targets in rhabdomyosarcoma [PDF]
, 2012 Resistance of rhabdomyosarcoma to current therapies remains one of the key issues in pediatric oncology. Since the success of most cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that ...
Fulda, Simone
core +1 more source
Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes. [PDF]
, 2020 The cell surface proteome, the surfaceome, is the interface for engaging the extracellular space in normal and cancer cells. Here we apply quantitative proteomics of N-linked glycoproteins to reveal how a collection of some 700 surface proteins is ...
Coon, Joshua +5 more
core
Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
Nature Communications, 2022 Cancers often harbor mutations in genes encoding important regulatory proteins, but therapeutic targeting of these molecules proves difficult due to their high structural similarity to their non-mutated counterpart. Here authors show the engineering of T
Andrew Poole +24 more
doaj +1 more source
VAV Proteins as Double Agents in Cancer: Oncogenes with Tumor Suppressor Roles
Biology, 2021 Guanosine nucleotide exchange factors (GEFs) are responsible for catalyzing the transition of small GTPases from the inactive (GDP-bound) to the active (GTP-bound) states. RHO GEFs, including VAV proteins, play essential signaling roles in a wide variety
Myriam Cuadrado, Javier Robles-Valero
doaj +1 more source
Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers [PDF]
Endocrinology and Metabolism, 2019 The development of next generation sequencing (NGS) has led to marked advancement of our understanding of genetic events mediating the initiation and progression of thyroid cancers. The NGS studies have confirmed the previously reported high frequency of
Iñigo Landa, Jeffrey A. Knauf
doaj +1 more source
Wnt/beta-catenin/Tcf signaling: A critical pathway in gastrointestinal tumorigenesis [PDF]
, 2002 Cancers of the gastrointestinal tract, including the liver, bile ducts, and pancreas, constitute the largest group of malignant tumors. Colorectal cancer is one of the most common neoplastic diseases in Western countries and one of the leading causes of ...
Bommer, G., Göke, B., Kolligs, F. T.
core +2 more sources
SUMOylation inhibits FOXM1 activity and delays mitotic transition [PDF]
, 2014 The forkhead box transcription factor FOXM1 is an essential effector of G2/M-phase transition, mitosis and the DNA damage response. As such, it is frequently deregulated during tumorigenesis. Here we report that FOXM1 is dynamically modified by SUMO1 but
Brosens, Jan J. +13 more
core +1 more source
Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. [PDF]
, 2014 Ewing sarcoma is the second-most-common bone cancer in children. Driven by an oncogenic chromosomal translocation that results in the expression of an aberrant transcription factor, EWS/FLI, the disease is typically aggressive and micrometastatic upon ...
Beckerle, Mary C +8 more
core +1 more source
Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins
Blood Cancer Discovery, 2021 Abstract The PML/RARα fusion protein is the oncogenic driver in acute promyelocytic leukemia (APL). Although most APL cases are cured by PML/RARα-targeting therapy, relapse and resistance can occur due to drug-resistant mutations.
Yasen Maimaitiyiming +38 more
openaire +2 more sources